NCT06748872 (EPITOME-1015-I) is a Phase 1 clinical trial of Lymphodepletion in Epithelial Ovarian Cancer, sponsored by Medigene AG.

Who is sponsoring NCT06748872?

NCT06748872 is sponsored by Medigene AG.

What drugs are being tested in NCT06748872?

Interventions in NCT06748872: Lymphodepletion, TCR-T cells (MDG1015).

What condition does NCT06748872 study?

NCT06748872 studies Epithelial Ovarian Cancer, Gastro-esophageal Junction Cancer, Soft Tissue Sarcoma (STS), Myxoid Liposarcoma, Synovial Sarcoma.

Is NCT06748872 still recruiting?

NCT06748872 is currently not yet recruiting. Last updated 27 December 2024.

Last reviewed 2024-12-27 · How we verify

NCT06748872: EPITOME-1015-I

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

EPITOME-1015-I: a Study to Investigate the Safety and Tolerability of MDG1015 in Patients with Epithelial Ovarian Cancer, Gastroesophageal Adenocarcinoma, Round Cell Liposarcoma And/or Synovial Sarcoma

Not yet recruiting Phase 1 Last updated 27 December 2024

What this trial tests

Phase 1 trial testing Lymphodepletion in Epithelial Ovarian Cancer in 55 participants. Not yet recruiting.

Timeline

1 July 2025

Primary endpoint
1 December 2027

1 August 2042

Quick facts

Lead sponsor	Medigene AG
Phase	Phase 1
Status	Not yet recruiting
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	55
Start date	1 July 2025
Primary completion	1 December 2027
Estimated completion	1 August 2042
Sites	1 location across United States

Drugs / interventions tested

Lymphodepletion — full drug profile →
TCR-T cells (MDG1015) — full drug profile →

Conditions studied

Epithelial Ovarian Cancer — all drugs for Epithelial Ovarian Cancer →
Gastro-esophageal Junction Cancer — all drugs for Gastro-esophageal Junction Cancer →
Soft Tissue Sarcoma (STS) — all drugs for Soft Tissue Sarcoma (STS) →
Myxoid Liposarcoma — all drugs for Myxoid Liposarcoma →

Sponsor

Medigene AG — full company profile →

Who can join

18 and older, any sex, with Epithelial Ovarian Cancer or Gastro-esophageal Junction Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

MDG1015 is a third generation TCR-T therapy product targeting NY-ESO-1/LAGE-1a armored and enhanced by the PD1-41BB costimulatory switch protein (CSP). The study purpose is to establish the safety, tolerability and preliminary efficacy of MDG1015 in patients with epithelial ovarian cancer, gastroesophageal adenocarcinoma, round cell liposarcoma and/or synovial sarcoma that expresses NY-ESO-1 and/or LAGE-1a. The main questions this clinical trial aims to answer are: Can this TCR-T therapy MDG1015 be given to patients safely? What is the optimal dose of the TCR-T therapy MDG1015? If and what side effects do participants experience after receiving the TCR-T therapy MDG1015? Do participants experience a potential disease response after receiving the TCR-T therapy MDG1015? Participants will: Receive (in most cases) 1 single infusion of MDG1015 at a pre-defined dose level and will be followed up regularly up to 1 year. After one year, participants will enter the long term follow-up part up to 15 years after being treated. Any side effects and/or potential disease response will be documented during this period.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

T-cell receptor therapy in ovarian cancer: concepts and challenges.
Wang X, Li Z, Zhang M, Yu Y, et al · · 2025 · PMID 41233888 · DOI 10.1186/s13048-025-01831-y

Verify or expand the search:

Other trials of Lymphodepletion

Trials testing the same drug.

NCT06912529 — Axicabtagene Ciloleucel CAR T-cells in Patients With Relapsed or Refractory Primary Mediastinal B-cell Lymphoma · Phase 2 · terminated
NCT01659151 — Vemurafenib With Lymphodepletion Plus Adoptive Cell Transfer & High Dose IL-2 Metastatic Melanoma · Phase 2 · completed

Other recruiting trials for Epithelial Ovarian Cancer

Currently open trials in the same condition.

NCT07432633 — [18F]FPyQCP PET Imaging of Fibroblast Activation Protein in Selected Oncology Indications · Phase 1, PHASE2 · recruiting
NCT07480954 — Dual-Targeting CAR-NK Cells for Recurrent Ovarian Cancer (MSLN, FRα, MUC16) · Phase 1, PHASE2 · recruiting
NCT07218809 — AZD5335 vs. Mirvetuximab Soravtansine in FRα-high and AZD5335 vs. Chemotherapy in FRα-low Platinum-resistant Ovarian Can · Phase 3 · recruiting
NCT07495397 — Single-arm, Prospective Clinical Trial of Efficacy and Safety of Daphnetin Capsules Combined With TC Regimen for Targete · NA · recruiting
NCT06915025 — Phase 3 Trial Evaluating the Safety & Efficacy of IMNN-001 Administered in Combination w/ Standard NACT & Adjuvant Chemo · Phase 3 · recruiting

Other Medigene AG trials

Trials by the same sponsor.

NCT03503968 — TCR Modified T Cells MDG1011 in High Risk Myeloid and Lymphoid Neoplasms · Phase 1, PHASE2 · terminated

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT06748872 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Medigene AG
Last refreshed: 27 December 2024

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06748872.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing